We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.
Community Guidelines: bit.ly/2MgAcio
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
We are dedicated to capturing the scientific opportunities of our time. With our early roots in Sweden, we started as pioneers in haemophilia. Today we are an innovative leader within rare diseases with a global reach. Together we are bringing brilliant ideas to life.
Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Recipharm is a leading global CDMO dedicated to meeting your evolving needs through operational excellence, scientific know-how, and customer connectivity.
We operate development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering.
Our worldwide reach paired with in-depth, localised market knowledge allows us to anticipate our customers’ needs and strengthen the support we provide to forge a healthier, more expansive and more fruitful future together.
With a workforce of 4,500 people, we are focused on supporting pharmaceutical companies with our full-service offering, taking products from early development through to commercial production. Since our inception in 1995, we have supported our customers throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again to ensure their products are delivered with certainty.